# A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

> **NCT06439771** · PHASE2 · RECRUITING · sponsor: **MediLink Therapeutics (Suzhou) Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** YL202 should be intravenously infused

## Key facts

- **NCT ID:** NCT06439771
- **Lead sponsor:** MediLink Therapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-23
- **Primary completion:** 2026-07-30
- **Final completion:** 2028-07-29
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06439771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06439771, "A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06439771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*